Clinical Trial Detail

NCT ID NCT01814826
Title Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

MLN4924

Azacitidine

Age Groups: senior

No variant requirements are available.